Plus, news about Agile Therapeutics, Insud, Werewolf Therapeutics and Allakos:
Taysha Gene Therapies sells $75M in shares: The biotech is issuing more than 14 million shares of common stock for $2.25 apiece and offering pre-funded warrants to certain investors. The company’s shares $TSHA dropped 36% last week after it unveiled Phase 1/2 data for its Rett syndrome gene therapy candidate. — Ayisha Sharma
Augustine raises $18.5M in Series A: The Belgian biotech brought in €17 million in the first close of its Series A. Its investors include Eli Lilly, Asabys Partners and V-Bio Ventures, among others. The biotech is focused on neurodegenerative and cardiometabolic diseases, both of which are familiar categories to Lilly. — Kyle LaHucik
Agile Therapeutics merges with Insud: Agile, a women’s health company, will be acquired by Exeltis Project, a subsidiary of Spain-based Insud, at an enterprise value of $45 million. — Kyle LaHucik
Werewolf Therapeutics unveils initial Ph1 cancer data: The company’s WTX-330 achieved “therapeutically relevant exposure levels” in subjects with locally advanced or metastatic solid tumors or non-Hodgkin lymphoma. The selectively activated IL-12 prodrug was linked with one unconfirmed partial response in a metastatic melanoma patient. — Ayisha Sharma
Allakos teases derm drug data in healthy subjects: The biotech’s monoclonal antibody candidate, AK006, reached serum concentrations consistent with mast cell inhibition in preclinical models. Allakos’ Phase 1 trial is also enrolling people with chronic spontaneous urticaria. The company’s shares $ALLK were down around 7% when the market opened. — Ayisha Sharma